Brentuximab vedotin

Therapeutic Indications

Brentuximab vedotin is indicated for:

Hodgkin lymphoma (HL) CD30+

Irrespective of gender only Adults (18 years old or older)

Brentuximab vedotin is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).

Brentuximab vedotin is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).

Brentuximab vedotin is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):

  1. following ASCT, or
  2. following at least two prior therapies when ASCT or multi -agent chemotherapy is not a treatment option.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.2-1.8 mg/kg once every 2-3 weeks

Cutaneous T-cell lymphoma (CTCL) with CD30+

Irrespective of gender only Adults (18 years old or older)

Brentuximab is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.8 mg/kg once every 3 weeks

Systemic anaplastic large cell lymphoma (sALCL)

Irrespective of gender only Adults (18 years old or older)

Brentuximab vedotin is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.8 mg/kg once every 3 weeks

Contraindications

Active ingredient Brentuximab vedotin is contraindicated in the following cases:

Bleomycin

No gender/age discrimination

There were no formal drug-drug interaction studies with brentuximab vedotin and bleomycin(B). In a phase 1 dose finding and safety study (SGN35-009), unacceptable pulmonary toxicity (including 2 fatal events) was noted in 11 of 25 patients (44%) treated with brentuximab vedotin plus ABVD. No pulmonary toxicity or fatal events were reported with brentuximab vedotin + AVD. Therefore, co-administration of brentuximab vedotin with bleomycin is contraindicated.